Abstract
277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.
Original language | English (US) |
---|---|
Pages (from-to) | 458-460 |
Number of pages | 3 |
Journal | Oncology Research and Treatment |
Volume | 13 |
Issue number | 6 |
DOIs | |
State | Published - 1990 |
Keywords
- Induction therapy
- Maintenance treatment
- Multiple myeloma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research